LU0959058974
Franklin Biotechnology Discovery Fund
Overall Morningstar Rating
Rating Category: Other Equity
Morningstar Style Box
| Large | Size | |||
|---|---|---|---|---|
| Medium | ||||
| Small | ||||
| Value | Blend | Growth | ||
| Style | ||||
Historical Morningstar Ratings
| Years | 3 |
| Ratings | |
| Number of Funds In Category |
| Years | 5 |
| Ratings | |
| Number of Funds In Category |
| Years | 10 |
| Ratings | |
| Number of Funds In Category |
This is a marketing communication. Please refer to the prospectus of the UCITS and to the KID before making any final investment decisions.
Overview
- Summary of Fund Objective
- Sustainability-related Disclosures
- Investor Profile
- What Are The Key Risks?
Summary of Fund Objective
To seek long-term investment growth, through growth of capital. The Fund mainly invests in equities of biotechnology companies and discovery research firms of any market capitalisation. This may include companies involved with genomics, genetic engineering and gene therapy as well as companies involved in the application and development of biotechnology in areas such as health care, pharmaceuticals, and agriculture. These investments may be from anywhere in the world, although the Fund may invest significantly in the US.
Sustainability-related Disclosures
The Fund promotes environmental and social characteristics in accordance with Article 8 of the Sustainable Finance Disclosure Regulation (the “SFDR”) and aims to invest in companies with positive environmental, social, governance (“ESG”) results.
In its implementation of the Fund’s ESG strategy, the Investment Manager favours issuers with a high-quality and/or an improving ESG profile, as captured by its proprietary ESG methodology. In addition, the Fund applies specific ESG exclusions.
The Fund’s environmental or social characteristics are assessed both quantitatively and qualitatively, by means of sustainability indicators as well as of the Investment Manager’s proprietary ESG methodology and its research and engagement process further described in the Website disclosure’s dedicated sections. As part of its investment decision making process, the Fund’s ESG strategy also uses binding criteria for the selection of underlying assets.
Finally, the Fund has a minimum allocation of 10% of its portfolio to sustainable investments. The Fund ensures that its sustainable investments do not cause significant harm to any environmental or social sustainable investment objective.
Investor Profile
- Seeking capital appreciation by investing in equity securities.
- Seeking a growth investment in the biotechnology sector in the U.S. and around the world.
- Planning to hold their investment for the medium to long term.
What Are The Key Risks?
The value of shares in the Fund and income received from it can go down as well as up and investors may not get back the full amount invested. Performance may also be affected by currency fluctuations. Currency fluctuations may affect the value of overseas investments.
- The Fund invests mainly in equity securities of biotechnology companies. Such securities have historically been subject to significant price movements that may occur suddenly due to market, sector or company-specific factors. As a result, the performance of the Fund can fluctuate significantly over relatively short time periods.
- Other significant risks include:
Liquidity risk: the risk that arises when adverse market conditions affect the ability to sell assets when necessary. Such risk may be triggered by (but not limited to) unexpected events such as environmental disasters or pandemics. Reduced liquidity may have a negative impact on the price of the assets.
Equity risk: prices of equities may be affected by factors such as economic, political, market, and issuer-specific changes. Such changes may adversely affect the value of the equities regardless of company-specific performance.
Securities Lending risk: the risk that default or insolvency of the borrower of securities lent by a Fund may lead to losses if collateral received realises less than the values of securities lent.
For full details of all of the risks applicable to this Fund, please refer to the “Risk Considerations” section of the Fund in the current prospectus of Franklin Templeton Investment Funds.
Fund Information
Fund Managers
Performance
- Discrete Annual Performance
- Cumulative Performance
- Annualised Performance
- Calendar Year Performance
- Risk Measures
Discrete Annual Performance
Discrete Annual Performance
Past performance does not predict future returns.
Chart
Month End As of 30.09.2025 | Currency | Sep-24 / Sep-25 | Sep-23 / Sep-24 | Sep-22 / Sep-23 | Sep-21 / Sep-22 | Sep-20 / Sep-21 | Sep-19 / Sep-20 | Sep-18 / Sep-19 | Sep-17 / Sep-18 | Sep-16 / Sep-17 | Sep-15 / Sep-16 | Performance Inception Date | Fund Overview | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A (acc) CHF-H1 (%) | CHF | 4,29 | 29,19 | 3,17 | -27,77 | -1,05 | 43,81 | -21,25 | -1,66 | 13,54 | -5,22 | 16.08.2013 | ||
| NASDAQ Biotechnology Index (%) | USD | 2,35 | 20,59 | 4,94 | -25,91 | 19,46 | 36,10 | -18,45 | 9,80 | 15,39 | -4,48 | — |
Month End As of 30.09.2025 | Currency | Sep-24 / Sep-25 | Sep-23 / Sep-24 | Sep-22 / Sep-23 | Sep-21 / Sep-22 | Sep-20 / Sep-21 | Sep-19 / Sep-20 | Sep-18 / Sep-19 | Sep-17 / Sep-18 | Sep-16 / Sep-17 | Sep-15 / Sep-16 | Performance Inception Date | Fund Overview | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A (acc) EUR-H1 (%) | EUR | 6,62 | 32,51 | 4,64 | -27,43 | -0,78 | 44,33 | -20,87 | — | — | — | 06.04.2018 | ||
| A (acc) HKD (%) | HKD | 8,76 | 34,30 | 7,18 | -24,95 | 0,64 | 44,75 | -17,97 | 1,51 | 17,08 | -3,71 | 26.02.2013 | ||
| A (acc) JPY-H1 (%) | JPY | — | — | — | — | — | — | — | — | — | — | 28.03.2025 | ||
| A (acc) SGD (%) | SGD | 9,03 | 27,18 | 2,26 | -21,29 | -0,34 | 44,60 | -17,17 | 2,01 | 15,71 | -7,81 | 25.10.2007 | ||
| A (acc) USD (%) | USD | 8,66 | 35,26 | 7,45 | -25,58 | 0,17 | 46,47 | -18,08 | 1,28 | 16,23 | -3,76 | 03.04.2000 | ||
| C (acc) USD (%) | USD | 8,02 | 34,50 | 6,84 | -26,01 | -0,42 | 45,60 | -18,54 | 0,68 | 15,57 | -4,30 | 01.09.2006 | ||
| F (acc) JPY-H1 (%) | JPY | — | — | — | — | — | — | — | — | — | — | 28.03.2025 | ||
| F (acc) USD (%) | USD | 7,61 | 33,94 | 6,34 | -26,30 | -0,75 | 45,01 | -18,91 | 0,26 | — | — | 21.04.2017 | ||
| N (acc) PLN-H1 (%) | PLN | 8,84 | 33,84 | 8,71 | -25,16 | — | — | — | — | — | — | 12.11.2020 | ||
| N (acc) USD (%) | USD | 7,83 | 34,27 | 6,67 | -26,15 | -0,57 | 45,38 | -18,68 | 0,52 | 15,35 | -4,45 | 29.12.2000 | ||
| W (acc) USD (%) | USD | 9,48 | 36,39 | 8,31 | -24,95 | 0,96 | 47,60 | -17,40 | 2,09 | 17,10 | -3,08 | 03.04.2000 | ||
| Z (acc) GBP (%) | GBP | 8,54 | 24,02 | -1,15 | -9,76 | -3,60 | 40,22 | -12,69 | 4,64 | 13,04 | 12,81 | 04.05.2012 | ||
| Z (acc) USD (%) | USD | 9,25 | 35,91 | 7,99 | -25,16 | 0,67 | 47,25 | -17,73 | 1,81 | 16,86 | -3,70 | 03.04.2000 |
The fund’s returns may increase or decrease as a result of changes to foreign exchange rates.
The value of shares in the Fund and income received from it can go down as well as up, and investors may not get back the full amount invested. Performance details provided are in share class currency, include the reinvested dividends gross of basic rate tax and are net of management fees. Sales charges and other commissions, other taxes and relevant costs to be paid by an investor are not included in the calculations.
Effective April 1, 2016, class B shares are closed to new investment and additional investment from existing holders.
Selected share classes show performance information prior to the launch date of that share class. In these cases, performance has been simulated by taking the performance data of a donor share class which has higher annual charges. Please follow this link for a full list of hybrid performance share classes.
Cumulative Performance
Cumulative Performance
Past performance does not predict future returns.
2013
2025
Chart
Month End As of 30.09.2025 | Currency | YTD | 1 Month | 3 Months | 6 Months | 1 Year | 3 Years | 5 Years | 10 Years | 15 Years | Performance Inception 16.08.2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A (acc) CHF-H1 (%) | CHF | 18,81 | 10,63 | 27,21 | 25,87 | 4,29 | 39,00 | -0,66 | 19,06 | — | 80,02 | |
| NASDAQ Biotechnology Index (%) | USD | 13,21 | 4,32 | 15,43 | 14,97 | 2,35 | 29,52 | 14,64 | 53,98 | 450,39 | 149,24 |
Month End As of 30.09.2025 | Currency | YTD | 1 Month | 3 Months | 6 Months | 1 Year | 3 Years | 5 Years | 10 Years | 15 Years | Performance Inception | Performance Inception Date | Fund Overview | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A (acc) EUR-H1 (%) | EUR | 20,62 | 10,85 | 27,94 | 26,99 | 6,62 | 47,84 | 6,46 | — | — | 36,90 | 06.04.2018 | ||
| A (acc) HKD (%) | HKD | 22,67 | 10,81 | 27,59 | 28,32 | 8,76 | 56,56 | 18,25 | 60,67 | — | 211,71 | 26.02.2013 | ||
| A (acc) JPY-H1 (%) | JPY | — | — | — | — | — | — | — | — | — | — | 28.03.2025 | ||
| A (acc) SGD (%) | SGD | 15,65 | 11,59 | 30,57 | 23,19 | 9,03 | 41,80 | 11,23 | 44,97 | 400,50 | 351,45 | 25.10.2007 | ||
| A (acc) USD (%) | USD | 22,44 | 10,99 | 28,71 | 28,33 | 8,66 | 57,92 | 17,73 | 60,03 | 410,69 | 380,55 | 03.04.2000 | ||
| C (acc) USD (%) | USD | 21,90 | 10,94 | 28,51 | 27,94 | 8,02 | 55,22 | 14,38 | 51,04 | 367,82 | 444,55 | 01.09.2006 | ||
| F (acc) JPY-H1 (%) | JPY | — | — | — | — | — | — | — | — | — | — | 28.03.2025 | ||
| F (acc) USD (%) | USD | 21,57 | 10,95 | 28,45 | 27,68 | 7,61 | 53,27 | 12,12 | — | — | 49,90 | 21.04.2017 | ||
| N (acc) PLN-H1 (%) | PLN | 22,59 | 11,06 | 28,65 | 28,36 | 8,84 | 58,36 | — | — | — | 14,50 | 12.11.2020 | ||
| N (acc) USD (%) | USD | 21,73 | 10,93 | 28,44 | 27,82 | 7,83 | 54,44 | 13,39 | 48,51 | 356,39 | 254,18 | 29.12.2000 | ||
| W (acc) USD (%) | USD | 23,17 | 11,04 | 28,97 | 28,83 | 9,48 | 61,73 | 22,55 | 73,12 | 460,89 | 427,80 | 03.04.2000 | ||
| Z (acc) GBP (%) | GBP | 14,39 | 11,60 | 31,50 | 23,54 | 8,54 | 33,06 | 15,75 | 89,08 | — | 385,95 | 04.05.2012 | ||
| Z (acc) USD (%) | USD | 22,93 | 11,06 | 28,89 | 28,70 | 9,25 | 60,35 | 20,81 | 67,67 | 435,09 | 403,52 | 03.04.2000 |
The fund’s returns may increase or decrease as a result of changes to foreign exchange rates.
The value of shares in the Fund and income received from it can go down as well as up, and investors may not get back the full amount invested. Performance details provided are in share class currency, include the reinvested dividends gross of basic rate tax and are net of management fees. Sales charges and other commissions, other taxes and relevant costs to be paid by an investor are not included in the calculations.
Effective April 1, 2016, class B shares are closed to new investment and additional investment from existing holders.
Selected share classes show performance information prior to the launch date of that share class. In these cases, performance has been simulated by taking the performance data of a donor share class which has higher annual charges. Please follow this link for a full list of hybrid performance share classes.
Annualised Performance
Annualised Performance
Past performance does not predict future returns.
Chart
Month End As of 30.09.2025 | Currency | 1 Year | 3 Years | 5 Years | 10 Years | 15 Years | Performance Inception 16.08.2013 | |
|---|---|---|---|---|---|---|---|---|
| A (acc) CHF-H1 (%) | CHF | 4,29 | 11,60 | -0,13 | 1,76 | — | 4,97 | |
| NASDAQ Biotechnology Index (%) | USD | 2,35 | 9,00 | 2,77 | 4,41 | 12,04 | 7,82 |
Month End As of 30.09.2025 | Currency | 1 Year | 3 Years | 5 Years | 10 Years | 15 Years | Performance Inception | Performance Inception Date | Fund Overview | |
|---|---|---|---|---|---|---|---|---|---|---|
| A (acc) EUR-H1 (%) | EUR | 6,62 | 13,92 | 1,26 | — | — | 4,29 | 06.04.2018 | ||
| A (acc) HKD (%) | HKD | 8,76 | 16,11 | 3,41 | 4,86 | — | 9,45 | 26.02.2013 | ||
| A (acc) JPY-H1 (%) | JPY | — | — | — | — | — | — | 28.03.2025 | ||
| A (acc) SGD (%) | SGD | 9,03 | 12,34 | 2,15 | 3,78 | 11,33 | 8,77 | 25.10.2007 | ||
| A (acc) USD (%) | USD | 8,66 | 16,45 | 3,32 | 4,81 | 11,48 | 6,35 | 03.04.2000 | ||
| C (acc) USD (%) | USD | 8,02 | 15,78 | 2,72 | 4,21 | 10,83 | 9,29 | 01.09.2006 | ||
| F (acc) JPY-H1 (%) | JPY | — | — | — | — | — | — | 28.03.2025 | ||
| F (acc) USD (%) | USD | 7,61 | 15,29 | 2,31 | — | — | 4,91 | 21.04.2017 | ||
| N (acc) PLN-H1 (%) | PLN | 8,84 | 16,56 | — | — | — | 2,81 | 12.11.2020 | ||
| N (acc) USD (%) | USD | 7,83 | 15,59 | 2,55 | 4,03 | 10,65 | 5,24 | 29.12.2000 | ||
| W (acc) USD (%) | USD | 9,48 | 17,38 | 4,15 | 5,64 | 12,18 | 6,74 | 03.04.2000 | ||
| Z (acc) GBP (%) | GBP | 8,54 | 9,99 | 2,97 | 6,58 | — | 12,52 | 04.05.2012 | ||
| Z (acc) USD (%) | USD | 9,25 | 17,04 | 3,85 | 5,30 | 11,83 | 6,55 | 03.04.2000 |
The fund’s returns may increase or decrease as a result of changes to foreign exchange rates.
The value of shares in the Fund and income received from it can go down as well as up, and investors may not get back the full amount invested. Performance details provided are in share class currency, include the reinvested dividends gross of basic rate tax and are net of management fees. Sales charges and other commissions, other taxes and relevant costs to be paid by an investor are not included in the calculations.
Effective April 1, 2016, class B shares are closed to new investment and additional investment from existing holders.
Selected share classes show performance information prior to the launch date of that share class. In these cases, performance has been simulated by taking the performance data of a donor share class which has higher annual charges. Please follow this link for a full list of hybrid performance share classes.
Calendar Year Performance
Calendar Year Performance
Past performance does not predict future returns.
Chart
Month End As of 30.09.2025 | Currency | YTD | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | Performance Inception Date | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A (acc) CHF-H1 (%) | CHF | 18,81 | -1,81 | 12,38 | -15,66 | -18,40 | 25,79 | 28,84 | -19,01 | 13,95 | -19,54 | 4,80 | 16.08.2013 | |
| NASDAQ Biotechnology Index (%) | USD | 13,21 | -1,37 | 3,74 | -10,91 | -0,63 | 25,69 | 24,41 | -9,32 | 21,06 | -21,68 | 11,42 | — |
Month End As of 30.09.2025 | Currency | YTD | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | Performance Inception Date | Fund Overview | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A (acc) EUR-H1 (%) | EUR | 20,62 | 0,80 | 14,55 | -15,11 | -18,22 | 26,32 | 29,15 | — | — | — | — | 06.04.2018 | ||
| A (acc) HKD (%) | HKD | 22,67 | 2,09 | 17,35 | -12,39 | -16,89 | 26,87 | 32,87 | -16,12 | 17,78 | -17,85 | 4,92 | 26.02.2013 | ||
| A (acc) JPY-H1 (%) | JPY | — | — | — | — | — | — | — | — | — | — | — | 28.03.2025 | ||
| A (acc) SGD (%) | SGD | 15,65 | 6,20 | 15,56 | -13,14 | -15,60 | 25,22 | 31,75 | -14,70 | 8,02 | -16,16 | 12,31 | 25.10.2007 | ||
| A (acc) USD (%) | USD | 22,44 | 2,64 | 17,29 | -12,51 | -17,36 | 27,52 | 33,53 | -16,31 | 16,93 | -17,87 | 4,93 | 03.04.2000 | ||
| C (acc) USD (%) | USD | 21,90 | 2,06 | 16,63 | -13,02 | -17,84 | 26,80 | 32,75 | -16,80 | 16,28 | -18,38 | 4,36 | 01.09.2006 | ||
| F (acc) JPY-H1 (%) | JPY | — | — | — | — | — | — | — | — | — | — | — | 28.03.2025 | ||
| F (acc) USD (%) | USD | 21,57 | 1,57 | 16,17 | -13,35 | -18,18 | 26,31 | 32,16 | -17,09 | — | — | — | 21.04.2017 | ||
| N (acc) PLN-H1 (%) | PLN | 22,59 | 2,08 | 17,61 | -11,39 | -18,85 | — | — | — | — | — | — | 12.11.2020 | ||
| N (acc) USD (%) | USD | 21,73 | 1,89 | 16,43 | -13,18 | -17,97 | 26,58 | 32,51 | -16,92 | 16,05 | -18,49 | 4,16 | 29.12.2000 | ||
| W (acc) USD (%) | USD | 23,17 | 3,43 | 18,31 | -11,84 | -16,70 | 28,54 | 34,61 | -15,60 | 17,75 | -17,23 | 5,73 | 03.04.2000 | ||
| Z (acc) GBP (%) | GBP | 14,39 | 5,02 | 11,80 | -1,66 | -16,03 | 24,15 | 29,17 | -10,92 | 7,20 | -1,24 | 11,55 | 04.05.2012 | ||
| Z (acc) USD (%) | USD | 22,93 | 3,16 | 17,87 | -12,07 | -16,91 | 28,20 | 34,20 | -15,91 | 17,46 | -17,65 | 4,93 | 03.04.2000 |
The fund’s returns may increase or decrease as a result of changes to foreign exchange rates.
The value of shares in the Fund and income received from it can go down as well as up, and investors may not get back the full amount invested. Performance details provided are in share class currency, include the reinvested dividends gross of basic rate tax and are net of management fees. Sales charges and other commissions, other taxes and relevant costs to be paid by an investor are not included in the calculations.
Effective April 1, 2016, class B shares are closed to new investment and additional investment from existing holders.
Selected share classes show performance information prior to the launch date of that share class. In these cases, performance has been simulated by taking the performance data of a donor share class which has higher annual charges. Please follow this link for a full list of hybrid performance share classes.
Risk Measures
Risk Measures
| Standard Deviation (%) | 3 Years | 5 Years | 10 Years |
|---|---|---|---|
| A (acc) CHF-H1 | 18,87 | 18,89 | 21,79 |
| Sharpe Ratio (%) | 3 Years | 5 Years | 10 Years |
|---|---|---|---|
| A (acc) CHF-H1 | 0,57 | -0,02 | 0,09 |
Portfolio
Assets
Positions
| Fund | Benchmark | |
|---|---|---|
| Number of Issuers | 80 | 251 |
Portfolio Statistics
| Fund | Benchmark | |
|---|---|---|
| Price to Book | 4,63x | 4,31x |
| Price to Cash Flow | 14,23x | 17,27x |
Portfolio Allocations
- Assets
- Geography
- Sector
- Market Capitalisation
Assets
Asset Allocation
Chart
| Fund | ||
|---|---|---|
| Equity | 95,34% | |
| Cash & Cash Equivalents | 4,66% |
Any negative cash position reflects a temporary position that is a result of a delay in securities settlement transactions.
Geography
Geographic Allocation
Chart
| Fund | Benchmark | ||
|---|---|---|---|
| 75,74% | 100,00% | ||
| 16,46% | — | ||
| 2,48% | — | ||
| 0,65% | — | ||
| 4,66% | — |
Any negative cash position reflects a temporary position that is a result of a delay in securities settlement transactions.
Sector
Sector Allocation
Chart
| Fund | Benchmark | ||
|---|---|---|---|
| Biotechnology | 78,75% | 79,74% | |
| Pharmaceuticals | 12,48% | 14,63% | |
| Health Care Services | 2,30% | 0,78% | |
| Life Sciences Tools & Services | 1,60% | 4,72% | |
| Managed Health Care | 0,21% | — | |
| Cash & Cash Equivalents | 4,66% | — |
Any negative cash position reflects a temporary position that is a result of a delay in securities settlement transactions.
Market Capitalisation
Market Capitalisation Allocation
Chart
| Fund | ||
|---|---|---|
| <2.0 Billion | 21,52% | |
| 2.0-5.0 Billion | 20,57% | |
| 5.0-10.0 Billion | 13,11% | |
| 10.0-25.0 Billion | 6,30% | |
| 25.0-50.0 Billion | 8,67% | |
| >50.0 Billion | 29,35% | |
| N/A | 0,48% |
Any negative cash position reflects a temporary position that is a result of a delay in securities settlement transactions.
Portfolio Holdings
- Holdings
- Top Ten Holdings
Holdings
Holdings
These securities do not represent all of the securities purchased, sold or recommended for clients, and the reader should not assume that investment in the securities listed was or will be profitable.
Top Ten Holdings
Top Equity Issuers
Chart
| Fund | ||
|---|---|---|
| GILEAD SCIENCES INC | 6,32% | |
| AMGEN INC | 4,93% | |
| VERTEX PHARMACEUTICALS INC | 4,82% | |
| ARGENX SE | 4,31% | |
| ALNYLAM PHARMACEUTICALS INC | 4,27% | |
| REGENERON PHARMACEUTICALS INC | 3,98% | |
| JAZZ PHARMACEUTICALS PLC | 3,83% | |
| UNIQURE NV | 3,71% | |
| INSMED INC | 3,34% | |
| ASCENDIS PHARMA A/S | 3,11% |
These securities do not represent all of the securities purchased, sold or recommended for clients, and the reader should not assume that investment in the securities listed was or will be profitable.
Pricing
Pricing History Chart
- 1 Month
- 3 Months
- 6 Months
- YTD
- 1 Year
- 3 Years
- 5 Years
- Since Inception
November 2025
| SuSunday | MoMonday | TuTuesday | WeWednesday | ThThursday | FrFriday | SaSaturday |
|---|---|---|---|---|---|---|
November 2025
| SuSunday | MoMonday | TuTuesday | WeWednesday | ThThursday | FrFriday | SaSaturday |
|---|---|---|---|---|---|---|
Chart
Past performance does not predict future returns. The value of shares in the Fund and income received from it can go down as well as up, and investors may not get back the full amount invested. Historical pricing details provided are in share class currency, calculated NAV, taking into account of reinvestments and capital gain or loss. Sales charges and other commissions, other taxes and relevant costs to be paid by an investor are not included in the calculations.
Highest / Lowest NAV
| Year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Highest NAV | CHF20,31 As on 31.10.2025 | CHF17,93 As on 16.07.2024 | CHF15,60 As on 27.12.2023 | CHF16,46 As on 03.01.2022 | CHF22,27 As on 08.02.2021 | CHF20,52 As on 23.12.2020 | CHF16,29 As on 24.12.2019 | CHF16,61 As on 29.01.2018 | CHF16,51 As on 05.10.2017 | CHF16,06 As on 05.01.2016 |
| Lowest NAV | CHF12,40 As on 08.04.2025 | CHF15,06 As on 30.12.2024 | CHF12,36 As on 27.10.2023 | CHF11,64 As on 13.06.2022 | CHF15,50 As on 06.12.2021 | CHF11,71 As on 16.03.2020 | CHF12,29 As on 09.10.2019 | CHF11,40 As on 24.12.2018 | CHF13,53 As on 03.01.2017 | CHF11,64 As on 08.02.2016 |
Historical Data - Daily Fund Prices
- 1 Month
- 3 Months
- 6 Months
- YTD
- 1 Year
- 3 Years
- 5 Years
- Since Inception
November 2025
| SuSunday | MoMonday | TuTuesday | WeWednesday | ThThursday | FrFriday | SaSaturday |
|---|---|---|---|---|---|---|
November 2025
| SuSunday | MoMonday | TuTuesday | WeWednesday | ThThursday | FrFriday | SaSaturday |
|---|---|---|---|---|---|---|
Historical Pricing Results From 30.09.2025 To 31.10.2025
| Date | NAV | NAV Change | NAV Change (%) |
|---|---|---|---|
| 31.10.2025 | CHF20,31 | CHF0,12 | 0,59% |
| 30.10.2025 | CHF20,19 | CHF0,26 | 1,30% |
| 29.10.2025 | CHF19,93 | CHF-0,15 | -0,75% |
| 28.10.2025 | CHF20,08 | CHF0,26 | 1,31% |
| 27.10.2025 | CHF19,82 | CHF0,42 | 2,16% |
| 24.10.2025 | CHF19,40 | CHF0,09 | 0,47% |
| 23.10.2025 | CHF19,31 | CHF-0,05 | -0,26% |
| 22.10.2025 | CHF19,36 | CHF-0,33 | -1,68% |
| 21.10.2025 | CHF19,69 | CHF-0,12 | -0,61% |
| 20.10.2025 | CHF19,81 | CHF0,29 | 1,49% |
| 17.10.2025 | CHF19,52 | CHF0,17 | 0,88% |
| 16.10.2025 | CHF19,35 | CHF0,10 | 0,52% |
| 15.10.2025 | CHF19,25 | CHF0,31 | 1,64% |
| 14.10.2025 | CHF18,94 | CHF0,02 | 0,11% |
| 13.10.2025 | CHF18,92 | CHF0,06 | 0,32% |
| 10.10.2025 | CHF18,86 | CHF-0,18 | -0,95% |
| 09.10.2025 | CHF19,04 | CHF0,26 | 1,38% |
| 08.10.2025 | CHF18,78 | CHF0,25 | 1,35% |
| 07.10.2025 | CHF18,53 | CHF0,11 | 0,60% |
| 06.10.2025 | CHF18,42 | CHF-0,04 | -0,22% |
| 03.10.2025 | CHF18,46 | CHF0,13 | 0,71% |
| 02.10.2025 | CHF18,33 | CHF0,12 | 0,66% |
| 01.10.2025 | CHF18,21 | CHF0,21 | 1,17% |
| 30.09.2025 | CHF18,00 | CHF0,19 | 1,07% |
Documents
Product Literature
Fact Sheet - Franklin Biotechnology Discovery Fund (A (acc) CHF-H1)
Regulatory Documents
Key Information Document - Franklin Biotechnology Discovery Fund A (acc) CHF-H1
Prospectus (English CH) - Franklin Templeton Investment Funds
Semi Annual Report - Franklin Templeton Investment Funds
Semi Annual Report (abridged) - Franklin Templeton Investment Funds
Annual Report (abridged) - Franklin Templeton Investment Funds
Annual Report - Franklin Templeton Investment Funds
Articles of Incorporation - Franklin Templeton Investment Funds (FTIF)
Additional Resources
Sales Tools - Applicable non-Valuation Days Calendar for 2025
Important Legal Information
This fund meets the requirements under Article 8 of the EU Sustainable Finance Disclosure Regulation (SFDR); the fund has binding commitments in its investment policy to promote environmental and/or social characteristics and any companies in which it invests should follow good governance practices.
Further information in relation to the sustainability-related aspects of the Fund can be found at franklintempleton.lu/SFDR. Please review all of the fund's objectives and characteristics before investing.
This material is intended to be of general interest only and should not be construed as investment advice. It does not constitute legal or tax advice and it is not an offer for shares or an invitation to apply for shares of the Luxembourg-domiciled SICAV Franklin Templeton Investment Funds (the "Fund” or “FTIF"). For the avoidance of doubt, if you make a decision to invest, you will be buying units/shares in the fund and will not be investing directly in the underlying assets of the fund.
Franklin Templeton (“FT”) provides no guarantee or assurance that the Fund’s investment objective will be attained. The value of shares in the Fund and income received from it can go down as well as up, and investors may not get back the full amount invested. Past performance does not predict future returns. Currency fluctuations may cause the value of a Fund’s investments to diminish or increase.
FT shall not be liable to any user of this document or to any other person or entity for the inaccuracy of information or any errors or omissions in its contents, regardless of the cause of such inaccuracy, error or omission. Any opinions expressed are the author's at publication date and they are subject to change without prior notice. Any research and analysis contained in this material has been procured by FT for its own purposes and is provided to you only incidentally. Data from third party sources may have been used in the preparation of this document and FT has not independently verified, validated or audited such data.
No shares of the Fund may be directly or indirectly offered or sold to residents of the United States of America. Shares of the Fund are not available for public distribution in all jurisdictions and prospective investors, who are not financial professionals, should consult their financial advisor before deciding to invest. The Fund may use financial derivatives or other instruments which may entail specific risks more fully described in the Fund's Documents.
Subscriptions to shares of the Fund should only be made on the basis of the Fund’s current Prospectus, and, where available, the relevant KID, accompanied by the latest available audited annual report and the latest semi-annual report if published thereafter. These documents can be found on our website at www.franklinresources.com/all-sites, obtained, free of charge, from your local FT representative or can be requested via FT's European Facilities Service which is available at www.eifs.lu/franklintempleton. The Fund's documents are available in English, Arabic, French, German, Italian, Polish and Spanish.
In addition, a Summary of Investor Rights is available from www.franklintempleton.lu/summary-of-investor-rights. The summary is available in English.
The sub-funds of FTIF are notified for marketing in multiple EU Member States under the UCITS Directive. FTIF can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 93a of the UCITS Directive.
Franklin Templeton International Services S.à r.l. – Supervised by the Commission de Surveillance du Secteur Financier - 8A, rue Albert Borschette, L-1246 Luxembourg - Tel: +352 46 66 67-1 - Fax: +352 342080 9861.
CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.
Indices are unmanaged, and one cannot invest directly in an index. They do not reflect any fees, expenses or sales charges.
Important data provider notices and terms available at www.franklintempletondatasources.com.
Source: Nasdaq OMX.
Issued in Switzerland by Franklin Templeton Switzerland Ltd, Talstrasse 41, CH-8001 Zurich. Paying agent in Switzerland is BNP Paribas Securities Services, Paris, succursale de Zurich, Selnaustrasse 16, 8002 Zurich.
Footnotes
The above listed Funds prices are unconfirmed unless stated otherwise and for information only, as they have not yet been verified by the Administrative Agent of the relevant Funds. Neither the Fund itself nor Franklin Templeton accepts responsibility for any reliance placed on the prices indicated and the information included in this data file. Purchase, exchange and redemptions of Shares can only be made on the basis of confirmed prices. Confirmed prices may be obtained after 12pm noon from Franklin Templeton.
The Ongoing Charges Figure (OCF) includes the fees paid to the management company, the investment manager and the depository, as well as certain other expenses. The OCF is calculated by taking the relevant main material costs paid out over the 12-month period indicated and dividing them by the average net assets over the same period. The OCF does not include all expenses paid by the fund (for example, it does not include what the fund pays for buying and selling securities). For a comprehensive list of the types of costs deducted from fund assets, see the prospectus. For recent all-in annual costs, as well as hypothetical performance scenarios that show the effects that different levels of return could have on an investment in the fund, see the KID.
The charges are the fees the fund charges to investors to cover the costs of running the Fund. Additional costs, including transaction fees, will also be incurred. These costs are paid out by the Fund, which will impact on the overall return of the Fund.
Fund charges will be incurred in multiple currencies, meaning that payments may increase or decrease as a result of currency exchange fluctuations.
All charges will be paid out by the Fund, which will impact on the overall return of the Fund.